SEC Form 4Delisted · Sep 15, 2026Coverage since Sep 3, 2025Open-market trades only
$APGE insider trading
Over the last 12 months, Apogee Therapeutics insiders reported no purchases and 43 sales totaling $409.1M across SEC Form 4 filings. 79% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $409.1M 43 events
- Events · 12m
- 43 Form 4 filings, grouped
- Insiders · 12m
- 8 distinct reporters
- 10b5-1 share
- 79% of events, not dollars
Side
Price · $APGE · 3Mvia TradingView
Top insiders · 12m
Henderson JaneChief Financial Officer13× · $2.1M
Dambkowski CarlChief Medical Officer13× · $10.3M
HENDERSON MICHAEL THOMASChief Executive Officer11× · $26.7M
Fairmount Funds Management LLC—2× · $133.5M
McKenna Mark C.—1× · —
All insider trades
44 events
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | McKenna Mark C.D | ▽ Sale to issuer | 20,000 | — | — | -100% | — |
| Sep 3, 2026 | JONES WILLIAM A JRD | ▽ Sale to issuer | 34,824 | — | — | -100% | — |
| Sep 3, 2026 | Dambkowski CarlChief Medical Officer · O | ▽ Sale to issuer | 168,498 | $135.06 | $186K | -100% | 2 tranches |
| Sep 3, 2026 | Fox Jennifer A.D | ▽ Sale to issuer | 34,824 | — | — | -100% | — |
| Sep 3, 2026 | Henderson JaneChief Financial Officer · O | ▽ Sale to issuer | 158,371 | — | — | -100% | — |
| Sep 3, 2026 | HENDERSON MICHAEL THOMASChief Executive Officer · O·D | ▽ Sale to issuer | 920,941 | — | — | -100% | — |
| Sep 3, 2026 | Shah Nimish PD | ▽ Sale to issuer | 1,750,000 | $135.11 | $236.4M | -100% | indirect |
| Sep 3, 2026 | Fairmount Funds Management LLCD | ▽ Sale to issuer | 443,187 | — | — | -100% | 3 tranches · indirect |
| Aug 5, 2026 | Dambkowski CarlChief Medical Officer · O | ▼ Sale | 5,500 | $134.17 | $738K | -3.2% | plan |
| Jul 8, 2026 | HENDERSON MICHAEL THOMASChief Executive Officer · O·D | ▼ Sale | 20,000 | $133.63 | $2.7M | -2% | plan |
| Jul 1, 2026 | Dambkowski CarlChief Medical Officer · O | ▼ Sale | 5,500 | $132.74 | $730K | -3% | plan |
| Jun 22, 2026 | Dambkowski CarlChief Medical Officer · O | ▼ Sale | 26,400 | $132.6 | $3.5M | -12.8% | plan |
| Jun 22, 2026 | HENDERSON MICHAEL THOMASChief Executive Officer · O·D | ▼ Sale | 80,000 | $132.54 | $10.6M | -7.3% | plan |
| Jun 10, 2026 | HENDERSON MICHAEL THOMASChief Executive Officer · O·D | ▼ Sale | 20,000 | $83.38 | $1.7M | -1.8% | plan · 6 tranches |
| Jun 3, 2026 | Dambkowski CarlChief Medical Officer · O | ▼ Sale | 5,500 | $78.71 | $433K | -2.6% | plan |
| May 6, 2026 | Dambkowski CarlChief Medical Officer · O | ▼ Sale | 5,500 | $84.14 | $463K | -2.6% | plan · 2 tranches |
| May 1, 2026 | Henderson JaneChief Financial Officer · O | ▼ Sale | 2,000 | $82.04 | $164K | -1.1% | plan · 3 tranches |
| Apr 16, 2026 | Henderson JaneChief Financial Officer · O | ▼ Sale | 2,000 | $90 | $180K | -1.1% | plan |
| Apr 8, 2026 | HENDERSON MICHAEL THOMASChief Executive Officer · O·D | ▼ Sale | 20,000 | $82.58 | $1.7M | -1.7% | plan · 3 tranches |
| Apr 1, 2026 | Dambkowski CarlChief Medical Officer · O | ▼ Sale | 5,500 | $84.84 | $467K | -2.6% | plan · 3 tranches |
| Apr 1, 2026 | Henderson JaneChief Financial Officer · O | ▼ Sale | 2,000 | $85.01 | $170K | -1.1% | plan · 2 tranches |
| Mar 25, 2026 | Henderson JaneChief Financial Officer · O | ▼ Sale | 2,000 | $85 | $170K | -1.1% | plan |
| Mar 11, 2026 | HENDERSON MICHAEL THOMASChief Executive Officer · O·D | ▼ Sale | 20,000 | $74.78 | $1.5M | -1.7% | plan · 3 tranches |
| Mar 4, 2026 | Dambkowski CarlChief Medical Officer · O | ▼ Sale | 5,500 | $71.06 | $391K | -2.6% | plan · 3 tranches |
| Mar 2, 2026 | Henderson JaneChief Financial Officer · O | ▼ Sale | 2,000 | $70.22 | $140K | -1.1% | plan · 4 tranches |
| Feb 11, 2026 | HENDERSON MICHAEL THOMASChief Executive Officer · O·D | ▼ Sale | 20,000 | $63.35 | $1.3M | -1.7% | plan · 3 tranches |
| Feb 4, 2026 | Dambkowski CarlChief Medical Officer · O | ▼ Sale | 5,500 | $65.79 | $362K | -2.5% | plan · 5 tranches |
| Feb 2, 2026 | Henderson JaneChief Financial Officer · O | ▼ Sale | 2,000 | $65.81 | $132K | -1.1% | plan · 3 tranches |
| Jan 22, 2026 | Fairmount Funds Management LLCD | ▼ Sale | 1,750,000 | $76.3 | $133.5M | -85.4% | indirect |
| Jan 14, 2026 | HENDERSON MICHAEL THOMASChief Executive Officer · O·D | ▼ Sale | 20,000 | $81.11 | $1.6M | -1.6% | plan · 6 tranches |
| Jan 7, 2026 | Dambkowski CarlChief Medical Officer · O | ▼ Sale | 18,700 | $77.84 | $1.5M | -8.1% | plan · 4 tranches |
| Jan 6, 2026 | Henderson JaneChief Financial Officer · O | ▼ Sale | 8,000 | $76.14 | $609K | -4.1% | plan · 3 tranches |
| Dec 19, 2025 | Henderson JaneChief Financial Officer · O | ▼ Sale | 1,500 | $80 | $120K | -0.8% | plan |
| Dec 10, 2025 | HENDERSON MICHAEL THOMASChief Executive Officer · O·D | ▼ Sale | 20,000 | $75.38 | $1.5M | -1.6% | plan · 3 tranches |
| Dec 4, 2025 | Dambkowski CarlChief Medical Officer · O | ▼ Sale | 10,900 | $75 | $818K | -3.9% | plan |
| Dec 4, 2025 | Henderson JaneChief Financial Officer · O | ▼ Sale | 1,500 | $75 | $113K | -0.8% | plan |
| Dec 4, 2025 | HENDERSON MICHAEL THOMASChief Executive Officer · O·D | ▼ Sale | 40,000 | $75.01 | $3.0M | -3.1% | plan |
| Nov 25, 2025 | Henderson JaneChief Financial Officer · O | ▼ Sale | 1,500 | $70 | $105K | -0.8% | plan |
| Nov 14, 2025 | Henderson JaneChief Financial Officer · O | ▼ Sale | 2,000 | $65 | $130K | -1% | plan |
| Nov 13, 2025 | HENDERSON MICHAEL THOMASChief Executive Officer · O·D | ▼ Sale | 20,000 | $63.01 | $1.3M | -1.5% | plan · 4 tranches |
| Nov 11, 2025 | Henderson JaneChief Financial Officer · O | ▼ Sale | 1,000 | $60 | $60K | -0.5% | plan |
| Nov 5, 2025 | Dambkowski CarlChief Medical Officer · O | ▼ Sale | 10,785 | $55.07 | $594K | -3.7% | plan · 4 tranches |
| Oct 1, 2025 | Dambkowski CarlChief Medical Officer · O | ▼ Sale | 5,110 | $39.8 | $203K | -1.8% | plan |
| Sep 3, 2025 | Dambkowski CarlChief Medical Officer · O | ▼ Sale | 2,725 | $37.87 | $103K | -1.2% | plan · 2 tranches |
Every $APGE filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Apogee Therapeutics filings can reach your inbox instead.
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $APGE feed.